Genetic blueprint guides lifesaving drug dosing for transplant kids
NCT ID NCT06529536
Summary
This study is testing a personalized approach to dosing a critical anti-rejection drug (tacrolimus) for children who have received an organ transplant. Researchers will use each child's unique genetic information and a computer model to predict the best dose, aiming to keep drug levels in a safe and effective range more consistently. The goal is to reduce the risks of organ rejection and drug side effects by getting the dose right faster.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID ORGAN TRANSPLANT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Royal Children's Hospital
RECRUITINGMelbourne, Victoria, 3052, Australia
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.